Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis

The clinical-stage drug candidate EBL-1003 (apramycin) represents a distinct new subclass of aminoglycoside antibiotics for the treatment of drug-resistant infections. It has demonstrated best-in-class coverage of resistant isolates, and preclinical efficacy in lung infection models. However, precli...

Full description

Saved in:
Bibliographic Details
Published in:EBioMedicine Vol. 73; p. 103652
Main Authors: Becker, Katja, Cao, Sha, Nilsson, Anna, Erlandsson, Maria, Hotop, Sven-Kevin, Kuka, Janis, Hansen, Jon, Haldimann, Klara, Grinberga, Solveiga, Berruga-Fernández, Talia, Huseby, Douglas L., Shariatgorji, Reza, Lindmark, Evelina, Platzack, Björn, Böttger, Erik C., Crich, David, Friberg, Lena E., Vingsbo Lundberg, Carina, Hughes, Diarmaid, Brönstrup, Mark, Andrén, Per E., Liepinsh, Edgars, Hobbie, Sven N.
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 01.11.2021
Elsevier
Subjects:
ISSN:2352-3964, 2352-3964
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first